News | June 09, 2024
Gavi outlines plans to support access to new vaccines
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Establishing Asymchem’s first manufacturing footprint in Europe
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Subscribe To Our Newsletter & Stay Updated
